LIGAND PHARMACEUTICALS INC
Ticker: 886163
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 78.75+23.6% | 63.69+23.1% | 51.72-55.2% | 115.46+142.4% | 47.63+5.1% | 45.33-12.5% | 51.81+24.8% | 41.53 |
| Total Income | 78.75+23.6% | 63.69+23.1% | 51.72-55.2% | 115.46+142.4% | 47.63+5.1% | 45.33-12.5% | 51.81+24.8% | 41.53 |
| EXPENSES | ||||||||
| Expenditure | 94.50+71.5% | 55.10+60.4% | 34.35-43.3% | 60.53+54.5% | 39.18-52.0% | 81.55+67.6% | 48.67-19.7% | 60.63 |
| Tax | -15.61-198.8% | 15.80+244.8% | -10.91-145.7% | 23.86+274.0% | 6.38+182.5% | -7.73-1031.3% | 0.83+106.2% | -13.48 |
| PROFIT | ||||||||
| PBT | -44.09-168.6% | 64.30+365.0% | -24.26-117.2% | 141.14+1157.9% | 11.22+122.4% | -50.18-691.5% | -6.34+90.3% | -65.39 |
| Net Profit | -28.49-158.7% | 48.51+463.4% | -13.35-111.4% | 117.27+2317.9% | 4.85+111.4% | -42.45-492.1% | -7.17+86.2% | -51.91 |
| KEY METRICS | ||||||||
| OPM % | -20.01%-33.50pp | 13.49%-20.09pp | 33.58%-14.00pp | 47.58%+29.85pp | 17.73%+97.62pp | -79.89%-85.95pp | 6.07%+52.06pp | -45.99% |
| NPM % | -36.17%-112.33pp | 76.16%+101.96pp | -25.80%-125.80pp | 100.00%+89.82pp | 10.18%+103.82pp | -93.64%-79.80pp | -13.84%+86.16pp | -100.00% |
| EPS | -1.43-159.1% | 2.42+461.2% | -0.67-111.2% | 5.99+2296.0% | 0.25+111.3% | -2.21-466.7% | -0.39+86.5% | -2.88 |
Corporate Events
Board MeetingLGND
20268Dec
Board Meeting
Investor Day to highlight company strategy, investment activ…
SEC Filing ↗ Board MeetingLGND
20265Jun
Board Meeting
The 2026 Annual Meeting of Stockholders was held to elect ei…
SEC Filing ↗